Pharmaceutical

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).

Jul 18, 2024 - 04:00
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).
Read the original article

Tags:

Previous Article

Scorpion Therapeutics secures $150m for oncology pipeline

Next Article

FDA issues CRL to Orexo’s NDA for opioid overdose medication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Texas Medical Board under pressure to define emergency exception to abortion ban

Texas Medical Board under pressure to define emergency ...

Feb 3, 2024

STAT+: Morphic study shows promise — and blockbuster potential — for a pill to treat ulcerative colitis

STAT+: Morphic study shows promise — and blockbuster po...

Apr 25, 2023

STAT+: Pharmalittle: Pharma execs call for reversal of abortion pill ruling; U.S. to spend $5 billion to speed Covid-19 treatments

STAT+: Pharmalittle: Pharma execs call for reversal of ...

Apr 11, 2023